


<b>U. S. PATENT AND TRADEMARK OFFICE</b> <b>U.S. DEPARTMENT OF COMMERCE</b>  <b>TRANSMITTAL LETTER TO THE UNITED STATES</b> <b>DESIGNATED/ELECTED OFFICE (DO/EO/US)</b> <b>CONCERNING A FILING UNDER 35 U.S.C. 371</b>		<b>ATTORNEY'S DOCKET NUMBER</b>  BY0028P
		<b>U.S. APPLICATION NO. (If known, see 37 CFR 1.5)</b>  <b>10/571861</b>
<b>INTERNATIONAL APPLICATION NO.</b> PCT/2004/014661	<b>INTERNATIONAL FILING DATE</b> September 14, 2004	<b>PRIORITY DATE CLAIMED</b> September 16, 2003
<b>TITLE OF INVENTION</b> NOVEL INDOLOPYRROLOCARBAZOLE DERIVATIVE WITH ANTITUMOR ACTIVITY		
<b>APPLICANT(S) FOR DO/EO/US</b> Koji Yamada, Satoshi Sumani, Masaaki Hirose, Mitsuru Ohkubo, Hirobaru Arakawa		
<p><b>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</b></p> <ol style="list-style-type: none"><li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li>3. <input type="checkbox"/> This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.</li><li>4. <input checked="" type="checkbox"/> The US has been elected (PCT Article 31).</li><li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed [35 U.S.C. 371(c)(2)]<ol style="list-style-type: none"><li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li><li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li><li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li></ol></li><li>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].<ol style="list-style-type: none"><li>a. <input checked="" type="checkbox"/> is attached hereto</li><li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li></ol></li><li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)].<ol style="list-style-type: none"><li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li><li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li><li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li><li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li></ol></li><li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].</li><li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].</li><li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].</li></ol> <p><b>Items 11 to 20 below concern other document(s) or information included:</b></p> <ol style="list-style-type: none"><li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li><li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li><li>13. <input checked="" type="checkbox"/> A preliminary amendment.</li><li>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</li><li>15. <input type="checkbox"/> A substitute specification.</li><li>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</li><li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13<sup>ter</sup>.2 and 37 CFR 1.821 - 1.825.</li><li>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C.154(d)(4).</li><li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).</li><li>20. <input checked="" type="checkbox"/> Other items or information: Copy of verification of English translation of international application</li></ol>		

APR 03 2006 14 MAR 2006

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 24pt; font-weight: bold; text-align: center;">10/571861</div>		INTERNATIONAL APPLICATION NO. PCT/2004/014661		ATTORNEY'S DOCKET NUMBER BY0028P	
The following fees are submitted:				CALCULATIONS	PTO USE ONLY
21.	<input checked="" type="checkbox"/> Basic national fee.....	\$300		\$300.00	
22.	<input checked="" type="checkbox"/> Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... All other situations.....	\$0 \$200		\$200.00	
23.	<input checked="" type="checkbox"/> Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an International Searching Authority..... International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB ..... All other situations.....	\$0 \$100 \$400 \$500		\$400.00	
<b>TOTAL OF 21, 22 and 23=</b>				<b>\$900.00</b>	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
- 100 =	0 /50	0 = 0	X \$250.00	\$0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)].					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	8 - 20 =	0	X \$50.00	\$0.00	
Independent Claims	1 - 3 =	0	X \$200.00	\$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00		
<b>TOTAL OF ABOVE CALCULATIONS (SUBTOTAL)</b>				<b>\$900.00</b>	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
<b>TOTAL NATIONAL FEE</b>				<b>\$900.00</b>	
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				+	
<b>TOTAL FEES ENCLOSED</b>				<b>\$900.00</b>	
				Amount to be refunded:	
				Amount to be charged:	
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>13-2755</u> in the amount of <u>\$900.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. <u>13-2755</u> . A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.</b>					
SEND ALL CORRESPONDENCE TO: <div style="border: 1px solid black; padding: 2px; display: inline-block;">Customer No. 000210</div>					
MERCK & CO., INC. Patent Department, RY60-30 P.O. Box 2000 126 East Lincoln Avenue Rahway, New Jersey 07065-0970					
DATE: <u>March 14, 2006</u>				 SIGNATURE	
PHONE #: <u>(732) 594-3903</u>				David A. Muthard NAME	
				<u>35,297</u> REGISTRATION NUMBER	

10/571861  
IAPG Rec'd PCT/PTO 14 MAR 2006

**Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING  
A FILING UNDER 35 U.S.C. 371**

**Attorney Docket No.:** BY0028P  
**International Appln No.:** PCT/2004/014661  
**International Filing Date:** September 14, 2004  
**Priority Date:** September 16, 2003  
**Title:** NOVEL INDOLOPYRROLOCARBAZOLE DERIVATIVE  
WITH ANTITUMOR ACTIVITY

**Inventors:** Koji Yamada  
Satoshi Sumani  
Masaaki Hirose  
Mitsuru Ohkubo  
Hirobaru Arakawa

**EXPRESS MAIL CERTIFICATE**

**DATE OF DEPOSIT** March 14, 2006

**EXPRESS MAIL NO.** EV 421342899 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS  
EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE  
DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR  
PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

**MAILED BY**

Kathy Sluthowale **DATE** 3-14-06

VERIFICATION OF TRANSLATION

I, Isao YOKOYAMA, a Japanese Patent Attorney registered No. 11604 having my business office at Banyu Pharmaceutical Co., Ltd., 2-3, Nihombashi Honcho 2-chome, Chuo-ku, Tokyo 103-8416, Japan, do hereby certify:

1. That I am familiar with the Japanese language and the English language; and
2. That, to the best of my knowledge and belief, the attached document represents a true and correct English language translation of the certified copy of PCT international Patent Application No. PCT/JP2004/014661, our case No. BY0028, which was filed with the Japan Receiving Office on September 14, 2004.

Signed at Tokyo, Japan, this 13th day of February, 2006



---

Isao YOKOYAMA